Antihypertensive treatment and serum lipoproteins.
Weidmann
P
P
Uehlinger
D E
DE
Gerber
A
A
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL; D003327:Coronary Disease / Q000209:etiology*; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000502:physiology; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000139:chemically induced; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007700:Kinetics; D008074:Lipoproteins / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008099:Liver / Q000378:metabolism; D008297:Male; D008593:Menopause; D012306:Risk; D012737:Sex Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D013565:Sympatholytics / Q000009:adverse effects / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D004232:Diuretics; D004967:Estrogens; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D049993:Sodium Chloride Symporter Inhibitors; D013565:Sympatholytics; D014280:Triglycerides; D014665:Vasodilator Agents; C030106:very low density lipoprotein triglyceride; D002784:Cholesterol